{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:58:22Z","timestamp":1790521102165,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma 2 (Bcl-2) is associated with a poor prognosis, and increased levels have been described in patients with \u201cdouble-hit\u201d diffuse large B-cell lymphoma, a subgroup of Burkitt\u2019s lymphoma, and patients with pediatric acute lymphoblastic leukemia harboring a t(17;19) translocation. Here, we show that the addition of venetoclax (VEN), a specific Bcl-2 inhibitor, potently enhanced the efficacy of the therapeutic anti-CD20 antibody rituximab, anti-CD38 daratumumab, and anti-CD19-DE, a proprietary version of tafasitamab. This was because of an increase in antibody-dependent cellular phagocytosis by macrophages as shown in\u00a0vitro and in\u00a0vivo in cell lines and patient-derived xenograft models. Mechanistically, double-hit lymphoma cells subjected to VEN triggered phagocytosis in an apoptosis-independent manner. Our study identifies the combination of VEN and therapeutic antibodies as a promising novel strategy for the treatment of B-cell malignancies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007364","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T17:53:53Z","timestamp":1657648433000},"page":"4847-4858","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis"],"prefix":"10.1182","volume":"6","author":[{"given":"Fotini","family":"Vogiatzi","sequence":"first","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heymann","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Winterberg","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Drakul","sequence":"additional","affiliation":[{"name":"2Division of Pediatric Oncology, and Children Research Center, University Childre\u0144s Hospital, Zurich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thies","family":"R\u00f6sner","sequence":"additional","affiliation":[{"name":"3Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Lenk","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Heib","sequence":"additional","affiliation":[{"name":"4Institute of Immunology, Christian-Albrechts-University Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Lynn","family":"Gehlert","sequence":"additional","affiliation":[{"name":"5Department of Medicine II, Division of Antibody-Based Immunotherapy, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Claviez","sequence":"additional","affiliation":[{"name":"1Pediatric Hematology\/Oncology, ALL-BFM Study Group, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Bornhauser","sequence":"additional","affiliation":[{"name":"2Division of Pediatric Oncology, and Children Research Center, University Childre\u0144s Hospital, Zurich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[{"name":"2Division of Pediatric Oncology, and Children Research Center, University Childre\u0144s Hospital, Zurich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5738","authenticated-orcid":false,"given":"Simon","family":"Bomken","sequence":"additional","affiliation":[{"name":"6Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Adam","sequence":"additional","affiliation":[{"name":"4Institute of Immunology, Christian-Albrechts-University Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9414-347X","authenticated-orcid":false,"given":"Fabian-Simon","family":"Frielitz","sequence":"additional","affiliation":[{"name":"7Institute of Social Medicine and Epidemiology, University of L\u00fcbeck, L\u00fcbeck, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-514X","authenticated-orcid":false,"given":"Britta","family":"Maecker-Kolhoff","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stanulla","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-8067","authenticated-orcid":false,"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[{"name":"3Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[{"name":"5Department of Medicine II, Division of Antibody-Based Immunotherapy, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kellner","sequence":"additional","affiliation":[{"name":"9Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M.","family":"Schewe","sequence":"additional","affiliation":[{"name":"10Department of Pediatrics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"issue":"9","key":"2022082518323321200_B1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"issue":"36","key":"2022082518323321200_B2","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022082518323321200_B3","doi-asserted-by":"crossref","first-page":"e1448331","DOI":"10.1080\/2162402X.2018.1448331","article-title":"Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"7","author":"Kellner","year":"2018","journal-title":"OncoImmunology."},{"issue":"10036","key":"2022082518323321200_B4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet."},{"issue":"19","key":"2022082518323321200_B5","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol."},{"issue":"23","key":"2022082518323321200_B6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med."},{"issue":"19","key":"2022082518323321200_B7","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022082518323321200_B8","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.3324\/haematol.2018.197640","article-title":"Daratumumab for relapsed\/refractory Philadelphia-positive acute lymphoblastic leukemia","volume":"103","author":"Ganzel","year":"2018","journal-title":"Haematologica."},{"issue":"5","key":"2022082518323321200_B9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood."},{"issue":"9","key":"2022082518323321200_B10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet."},{"issue":"4","key":"2022082518323321200_B11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.13624","article-title":"Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue","volume":"171","author":"Masqu\u00e9-Soler","year":"2015","journal-title":"Br J Haematol."},{"issue":"9","key":"2022082518323321200_B12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting BCL-2 in B-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022082518323321200_B13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med."},{"issue":"12","key":"2022082518323321200_B14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"2022082518323321200_B15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"2022082518323321200_B16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2022082518323321200_B17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."},{"key":"2022082518323321200_B18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic tumor cell resistance to the BCL-2 inhibitor venetoclax: a product of its microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front Oncol."},{"issue":"13","key":"2022082518323321200_B19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood-2017-01-764316","article-title":"An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts","volume":"130","author":"Schewe","year":"2017","journal-title":"Blood."},{"issue":"7","key":"2022082518323321200_B20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"16","key":"2022082518323321200_B21","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs."},{"issue":"12","key":"2022082518323321200_B22","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/leu.2015.153","article-title":"Effects of p38\u03b1\/\u03b2 inhibition on acute lymphoblastic leukemia proliferation and survival in\u00a0vivo","volume":"29","author":"Alsadeq","year":"2015","journal-title":"Leukemia."},{"issue":"10","key":"2022082518323321200_B23","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.1201321","article-title":"Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity","volume":"189","author":"Kellner","year":"2012","journal-title":"J Immunol."},{"issue":"1-2","key":"2022082518323321200_B24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jim.2011.08.003","article-title":"Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC","volume":"373","author":"Repp","year":"2011","journal-title":"J Immunol Methods."},{"key":"2022082518323321200_B25","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1401s83","article-title":"The isolation and characterization of murine macrophages","author":"Zhang","year":"2008"},{"issue":"1","key":"2022082518323321200_B26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood."},{"issue":"2","key":"2022082518323321200_B27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"venetoclax is effective in small-cell lung cancers with high BCL-2 expression","volume":"24","author":"Lochmann","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2022082518323321200_B28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"12","key":"2022082518323321200_B29","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"2022082518323321200_B30","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1038\/ncomms6275","article-title":"Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response","volume":"5","author":"Houthuijzen","year":"2014","journal-title":"Nat Commun."},{"issue":"18","key":"2022082518323321200_B31","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"2022082518323321200_B32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.cdd.4402044","article-title":"Broad-spectrum caspase inhibitors: from myth to reality?","volume":"14","author":"Chauvier","year":"2007","journal-title":"Cell Death Differ."},{"issue":"1","key":"2022082518323321200_B33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022082518323321200_B34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2022082518323321200_B35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"2022082518323321200_B36","doi-asserted-by":"crossref","first-page":"754541","DOI":"10.3389\/fonc.2021.754541","article-title":"NK cells in the tumor microenvironment as new potential players mediating chemotherapy effects in metastatic melanoma","volume":"11","author":"Garofalo","year":"2021","journal-title":"Front Oncol."},{"issue":"5","key":"2022082518323321200_B37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4161\/mabs.29670","article-title":"Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer","volume":"6","author":"Meyer","year":"2014","journal-title":"MAbs."},{"issue":"10","key":"2022082518323321200_B38","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"2022082518323321200_B39","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2017.01804","article-title":"New strategies using antibody combinations to increase cancer treatment effectiveness","volume":"8","author":"Corraliza-Gorj\u00f3n","year":"2017","journal-title":"Front Immunol."},{"issue":"1","key":"2022082518323321200_B40","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly","year":"2020","journal-title":"NAR Cancer."},{"key":"2022082518323321200_B41","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood-2018-99-116283","article-title":"First evidence of restoration of T and NK cell compartment after venetoclax treatment","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood."},{"issue":"11","key":"2022082518323321200_B42","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/eji.200425011","article-title":"Increased sensitivity of early apoptotic cells to complement-mediated lysis","volume":"34","author":"Attali","year":"2004","journal-title":"Eur J Immunol."},{"key":"2022082518323321200_B43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood."},{"issue":"3","key":"2022082518323321200_B44","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2013.12.041","article-title":"Sensitizing protective tumor microenvironments to antibody-mediated therapy","volume":"156","author":"Pallasch","year":"2014","journal-title":"Cell."},{"issue":"10","key":"2022082518323321200_B45","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.3324\/haematol.2018.188680","article-title":"Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies","volume":"103","author":"El\u00edas","year":"2018","journal-title":"Haematologica."},{"issue":"1","key":"2022082518323321200_B46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-017-0359-0","article-title":"The development and current use of BCL-2 inhibitors for the treatment of chronic lymphocytic leukemia","volume":"12","author":"Lampson","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"issue":"1-2","key":"2022082518323321200_B47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11010-020-03796-6","article-title":"Bcl-2\/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2","volume":"472","author":"Morimoto","year":"2020","journal-title":"Mol Cell Biochem."},{"issue":"12","key":"2022082518323321200_B48","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"2022082518323321200_B49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-019-0587-5","article-title":"DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma","volume":"34","author":"Choudhry","year":"2020","journal-title":"Leukemia."},{"key":"2022082518323321200_B50","doi-asserted-by":"crossref","first-page":"608167","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"2022082518323321200_B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2004.01959.x","article-title":"The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically?","volume":"113","author":"Gregory","year":"2004","journal-title":"Immunology."},{"issue":"16","key":"2022082518323321200_B52","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2022082518323321200_B53","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis."},{"issue":"7877","key":"2022082518323321200_B54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","article-title":"Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis","volume":"597","author":"Kamber","year":"2021","journal-title":"Nature."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4847\/1917917\/advancesadv2022007364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/16\/4847\/1917917\/advancesadv2022007364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T18:33:30Z","timestamp":1661452410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/16\/4847\/485872\/Venetoclax-enhances-the-efficacy-of-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":54,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,8,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007364","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}